Combination of vitamin D analogues and immunosuppressants potential clinical use

Clinical Immunotherapeutics

Volumn 6, Issue 6, 1996, Pages 465-478

  Branisteanu, Dumitru D ^a   Mathieu, Chantai ^a   Casteels, Kristina ^a   Bouillon, Roger ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LEXACALCITOL; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNITY; DRUG MECHANISM; IMMUNE SYSTEM; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029770502     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259368     Document Type: Article

References (168)

1. Briggs JD, A critical review of immunosuppressive therapy, Immunol Lett 1991 Jul; 29 (1-2): 89-94
2. St, Georgiev V, New synthetic immunomodulating agents. Trends Pharmacol Sei 1988 Dec; 9(12): 446-51
3. Morris RE, In vivo immunopharmacology of the macrolides FK506 and rapamycin: toward the era of rational immunosuppressive drug discovery, development and use, Transplant Proc 1991 Dec; 23 (6): 2722-4
4. Hess AD, Mechanisms of action ofcyclosporine: considerations for the treatment of autoimmune diseases, Clin Immunol Immunopathol 1993 Aug; 68 (2): 220-8
5. Manila PS, Ullman KS, Fiering S, et al, The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes, EMBO J 1990 Aug; 9(13): 4425-33
6. Bierer BE, Somers PK, Wandless TJ, et al, Probing immunosuppressant action with a nonnatural immunophilin ligand, Science 1990 Oct; 250 (4980): 556-9
7. Schreiber SL, Liu J, Albers MW, et al, Immunophilin-ligand complexes as probes of intracellular signalling pathways, Transplant Proc 1991 Dec; 23 (6): 2839-44
8. Sigal NH, Dumont FJ, Cyclosporin A, FK-506, and rapamycin: pharmacologie probes of lymphocyte signal transduction, Annu Rev Immunol 1992; 10: 519-60
9. Perico N, Remuzzi G, Cyclosporine-induced renal dysfunction in experimental animals and humans, Transplant Rev 1991; 5: 63-80
10. Parsons WH, Sigal NH, Wyvratt MJ, FK-506: a novel immunosuppressant, Ann NY Acad Sei 1991 Jun; 685: 22-36
11. Ohara K, Billington R, James RW, et al, Toxicologie évaluation of FK506. Transplant Proc 1990 Feb; 22 ( 1 ): 83-6
12. Morris RE, Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 1992; 6: 39-87
13. Calne RY, Lim S, Samaan A, et al, Rapamycin for immunosuppression in organ allografling. Lancet 1989 Jul; II (8660): 227
14. Sehgal SN, Bansbach CC, Rapamycin: in vitro profile of a new immunosuppressive macrolide. Ann NY Acad Sei 1993 Jun; 685: 58-67
15. DumontFJ, StaruchMJ, KoprakSL, étal, Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990 Jan; 144 (1): 251-8
16. Chang JY, Sehgal SN, Bansbach CC, FK5Ü6 and rapamycin: novel pharmacological probes of the immune response. Trends Pharmacol Sei 1991 Jun; 12 (6): 218-23
17. Kimball PM, Kerman RH, Kalian BD, Production of synergistic but nonidentical mechanisms of immunosuppression by rapamycin and cyclosporine. Transplantation 1991 Feb; 51 (2): 486-90
18. Terada N, Lucas JJ, Sziepesi A, et al, Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late GI phase of the cycle. J Cell Physiol 1993 Jan; 154:7-15
19. Bierer BE, Manila PS, Standaert RF, et al, Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sei USA 1990 Dec; 87 (23): 9231-5
20. Collier St J, Immunosuppressive drugs. Curr Opin Immunol 1990; 2 (6): 854-8
21. Platz KP, Sollinger HW, Hullett DA, et al, RS-61443: a new, potent immunosuppressive agent. Transplantation 1991 Jan; 51 (1): 27-31
22. Mason J, Pharmacology of cyclosporine (Sandimmune). VII. Pathophysiology and toxicology of cyclosporine in humans and animals. Pharmacol Rev 1990 Sep; 41 (3): 423-34
23. Morris PJ, Cyclosporine, FK506 and other drugs in organ transplantation. Curr Opin Immunol 1991 Oct; 3 (5): 748-51
24. Allison AC, Kowalski WJ, Muller CD, et al, Mechanisms of action of mycophenolic acid. Ann NY Acad Sei 1993 Nov; 696: 63-87
25. Makowka L, Chapman F, Cramer DV, Historical development of brequinar sodium as a new immunosuppressive drug for transplantation. Transplant Proc 1993 Jun; 25 (352): 2-7
26. Forrest TL, Ware RE, Howard T, et al, Novel mechanisms of brequinar sodium immunosuppression on T cell activation. Transplantation 1994 Oct; 58 (8): 920-6
27. Cherwinski HM, McCarley D, Schatzman R, et al. The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism. J Pharmacol Exp Ther 1995 Jan; 272 (I): 460-8
28. Amento EP, Vitamin D and the immune system. Steroids 1987 Jan-Mar; 49 (1-3): 55-72
29. Lemire JM, Inimunomodulatory role of 1,25-dihydroxyvitamin D.î. J Cell Biochem 1992 May; 49 ( I ): 26-31
30. Manolagas SC, Provvedini DM, Tsoukas CD, Interactions of 1,25-dihydroxyvitamin D-4 and the immune system. Mol Cell Endocrinol 1985 Dec; 43 (2-3): 113-22
31. Manolagas SC, Yu X-P, Girasole G, et al, Vitamin D and the hematolymphopoietic tissue: a 1994 update. Semin Nephrol 1994 Mar; 14(2): 129-43
32. Tokuda N, Mizuki N, Kasahara M, et al, 1,25-Dihydroxyvitamin Di down-regulation of HLA-DR on human peripheral blood monocytes. Immunology 1992 Feb; 75 (2): 349-54
33. Rigby WFC, Waugh MG, Decreased accessory cell function and costimulatory activity by 1,25-dihydroxy vitamin Di-treated monocytes. Arthritis Rheum 1992 Jan; 35 ( 1 ): 110-9
34. Xu H, Soruri A, Gieseler RKH, et al, 1,25-Dihydroxy vitamin DI exerts opposing effects to IL-4 on MHC class-II antigen expression, accessory activity, and phagocytosis of human monocytes. Scand J Immunol 1993 Dec; 38 (6): 535-40
35. Rigby WFC, Waugh M, Graziano RF, Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1.25-dihydroxyvitamin D. Blood 1990 Jul: 76(1): 189-9?'
36. Madden JW, Smith DL, Immunopharmacology: immunomodulation and immunotherapy. JAMA 1992 Nov; 268 (20): 2964-9
37. Bach JF, Therapeutic strategies in autoimmune diseases: the search for tolerance induction. Transplant Proc 1994 Dec: 26 (6): 3188-90
38. Reiche] H, Koeffler HP, Norman AW. The role of the vitamin D endocrine system in health and disease. N Engl J Med 1989 Apr; 320(15): 980-91
39. Norman AW, Bone biochemistry and physiology from the perspectives of the vitamin D endocrine system. Curr Opin Rheumatol 1992 Jun; 4 (3): 375-82
40. DeLuca HF, Krisinger J. Darwish H. The vitamin D system: 1990. Kidney Int 1990 Sep: 38 Suppl. 29: S2-8
41. Girasole G, Passeri R, Jilka RL, et al. Interleukin-I I : a new cytokine critical for osteoclast development. J Clin Invest 1994 Apr; 93: 1516-24
42. Shinar DM, Rodan GA. Biphasic effects of transforming growth factor- on the production of osteoclast-like cells in mouse bone marrow cultures: the role of prostaglandins in the gen eration of these cells. Endocrinology 1990 Jun: 126 (6): 3153-8
43. Mac-Donald P, Dowd DR, Haussier MR. New insight in the structure and functions of the vitamin D receptor. Semin Nephrol 1994 Mar; 14(2): 101-18
44. Carlberg C, Mechanisms of nuclear signalling by vitamin Di: interplay with retinoid and thyroid hormone signalling. Eur J Biochem 1995; 231: 517-27
45. Whitfield GK, Hsieh J-C, Jurutka PW. et al. Genomic actions of 1.25-dihydroxy vitamin Di.JNutr 1995 Jun; 125 (6 Suppl.): 1690S-4S
46. Yu VC, Näar AM, Rosenfeld MG. Transcriptional regulation by the nuclear receptor superfamily. Curr Opin Biotechnol 1992: 3: 597-602
47. Darwish H, DeLuca HF. Vitamin D-regulated gene expression. CritRev Eukariot Gene Expr 1993: 3 (2): 89-116
48. Norman AW, Nemere I, Zhou L-X, et al. I.25(OH)2-vitamin D, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol 1992 Mar; 41 (3-8): 231-40
49. de Boland AR, Nemere 1. Rapid actions of vitamin D compounds. J Cell Biochem 1992 May; 49 ( I): 32-6
50. Nemere 1, Nongenomic effects of 1.25-dihydroxy vitamin Di: potential relation of a plasmalemmal receptor to the acute enhancement of intestinal calcium transport in chick. J Nutr 1995 Jun; 125 (6 Suppl.): 1695S-8S
51. Baran DT, Ray R, Sorensen AM. et al. Binding characteristics of a membrane receptor that recognizes lct.25-dihydroxyvitamin D and its epimer. l .25-dihydroxyvitainin Di. J Cell Biochem 1994 Jul: 56: 510-7
52. de Boland AR, Norman A, Evidence for involvement of protein kinase C and cyclic adenosine 3'.5'-monophosphate-dependent protein kinase in the 1.25-dihydroxy-vitamin Di-mediated rapid stimulation of intestinal calcium transport (transcaltachia). Endocrinology 1990 Jul: 127 (1): 39-45
53. Beno DWA, Brady LM. Bissonnette M, et al. Protein kinase C and mitogen-activated protein kinase are required for 1,25dihydroxyvitamin Di-stimulated Egr induction. J Biol Chem 1995 Feb:27()(8): 3642-7
54. Slater SJ, Kelly MB, Taddeo FJ, et al. Direct activation of protein kinase C by I
55. Bellido T, Morelli S, FernandeJ, LM. et al. Evidence for the participation of protein kinase C and 3'.5'-cyclic AMP-de-pendent protein kinase in the stimulation of the muscle cell proliferation by 1.25-dihydroxy-vitamin Di. Mol Cell En docrinol 1993 Jan; 90 (2): 231-8
56. Binswanger U, Helmle-Kolb C, Forgo J, et al. Rapid stimulation of Na /H exchange by 1.25-dihydroxyvitamin Dt: interaction with parathyroid-hormone-dependent inhibition. Pflugers Arch 1993 Sep; 424 (5-6): 391-7
57. Selles J, Boland R. Evidence on the participation of the 3',5'cyclic AMP pathway in the non-genomic action of 1,25-dihydroxy-vitamin Dt in cardiac muscle. Mol Cell Endocrinol 1991 Dec: 82 (2-3): 229-35
58. Sherwood LM, Russell J. The role of I,25(OH):D.i in regulating parathyroid gland function. Proc Soc Exp Biol Med 1989 Jul: 191 (.V):23-V7
59. Berg JP, Torjesen PA. Haug E. Calcitriol attenuates iodide uptake in a rat thyroid cell line. In: Norman AW, Bouillon R, Thomasset M. editors. Vitamin D, Gene regulation, structurefunction analysis and clinical application. Berlin: Walter de Gruyter, 1991: 401-2
60. Naveh-Many T, Silver J. Regulation of calcitonin gene transcription by vitamin D metabolites in I'ivtt in rat. J Clin Invest 1988 Jan; 81 (I): 270-3
61. Nyomba BL, Bouillon R. de Moor P. Influence of vitamin D status on insulin secretion and glucose tolerance in the rabbit. Endocrinology 1984 Jul: 115(1): 191-7
62. Cade C, Norman AW, Vitamin Di improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat m v/w. Endocrinology 1986 Jul; 119(1): 84-90
63. ClarkSA, Stumpf WE, Sur M, et al. 1,25-Dihydroxy vitamin Dî target cells in immature pancreatic islets. Am J Physiol 1987 JuM 253(1 Pt IJ.-E99-105
64. Labriji-Mestaghanmi H, Billaudel B. Gamier PE. et al. Vitamin D and pancreatic islet function. J Endocrinol Invest 1988 Sep; II (8): 577-93
65. d'Emden MC, Dunlop M. Larkins RG. et al. The in vitro effect of la,25-dihydroxyvitamin Dî on insulin production by neonatal rat islets. BiochemBiophys Res Commun 1989 Oct: 164 (1): 413-8
66. Billaudel BJL, Faure AC. Suiter BCJ. Effect of 1,25-dihydroxyvitamin D-4 on isolated islets from vitamin Dj-deprived rats. Am J Physiol 1990 Apr; 258 (4 Pt 1 ): E643-8
67. Tornquist K, Effect of 1.25-dihydroxyvitamin Di on rat pituitary prolactin release. Acta Endocrinol (Copenh) 1987 Dec; 116 (4): 459-64
68. d'Emden MC, Wark JD, 1.25-Dihydroxy vitamin Dï enhances thyrotropin-releasing hormone-induced thyrotropin secretion in normal pituitary cells. Endocrinology 1987 Sep; 121 (3): 1192-4
69. Kaji H, Hinkle PM. Attenuation of thyroid hormone action by 1.25-dihydroxyvitamin D< in pituitary cells. Endocrinology 1989 Feb; 124(2): 930-6
70. Osinundsen BC, Huang HFS. Anderson MB. et al. Multiple sites of action of the vitamin D endocrine system: FSH stim ulation of testis 1,25-dihydroxyvitamin Di receptors. J Steroid Biochem 1989; 34 (1-6): 339-43
71. Dokoh S, Donaldson CA, Marion SL, et al. The ovary: a target organ for 1.25-dihydroxyvitamin Di. Endocrinolocy 1983 Jan; 112(1): 200-6
72. Baksi SN, Hughes MJ. Alteration of adrenal catecholamine levels in the rat after dietary calcium and vitamin D deficiencies. J Autonom Nerv Syst 1984 Dec: 11 (4): 393-6
73. Smith EL, Holick MF. The skin: the site of vitamin Dî synthesis and a target tissue for its metabolite 1.25-dihydroxyvitamin D,. Steroids 1987 Jan-Mar; 49 (1-3): 103-31
74. Bukoski RD, De Wan P, McCarron DA, 1,25(OH)2 vitamin D, modifies growth and contractile function of vascular smooth muscle of spontaneously hypertensive rats. Am J Hypertens 1989 Jul; 2 (7): 553-6
75. Baksi SN, Hughes MJ, Deficiency in dietary vitamin D, not calcium, alters noradrenergic responsiveness in rat atria in vitro. J Mol Cell Cardiol 1986 Jul; 18 (7): 653-6
76. Weishaar RE, Simpson RU, Involvement of vitamin Di with cardiovascular function. II. Direct and indirect effects. Am J Physiol 1987 Dec; 253 (6 Pt I ): E675-83
77. Boland R, Role of vitamin D in skeletal muscle function. Endocr Rev 1986Nov;7(4):434-8
78. Luine VN, Sonnenberg J, Christakos S, Vitamin D; is the brain a target? Steroids 1987 Jan-Mar; 49 (1-3): 133-53
79. Marin L, Dufour ME, Tordet C, et al, 1,25(OH)2D, stimulates phospholipid biosynthesis and surfactant release in fetal rat lung explants. Biol Neonate 1990; 57 (3-4): 257-60
80. Brown G, Bunce CM, Rowlands DC, et al, All-trans retinoic acid and 1,25-dihydroxy vitamin Di co-operate to promote differentiation of the human promyeloid leukemia cell line HL60 to monocytes. Leukemia 1994 May; 8 (5): 806-15
81. Provvedini DM, Tsoukas CD, Deftos LJ, et al, l ,25-Dihydroxyvitamin Di receptors in human leukocytes. Science 1983 Sep; 221 (4616); 1181-3
82. Merke J, Senst S, Ritz E, Demonstration and characterization of 1,25-dihydroxyvitamin D.i receptors in human mononuclear blood cells. Biochem Biophys Res Commun 1984 Apr; 120(1); 199-205
83. Provvedini DM, Manolagas SC, la,25-Dihydroxyvitamin Di receptor distribution and effects in subpopulations of normal human T lymphocytes. J Clin Endocrinol Metab 1989 Apr; 68 (4): 774-9
84. Provvedini DM, Tsoukas CD, Deftos LJ, et al, la,25-Dihydroxyvitamin Di-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 1986 Apr; 136(8): 2734-40
85. Morgan JW, Salyanarayana Reddy G, Uskokovic MR, et al, Functional block for lcc,25-dihydroxyvitamin D.cmediated gene regulation in human B lymphocytes. J Biol Chem 1984 May; 269 (18): 13437-43
86. Koeffler HP, Reichel H, Bishop JE, y-Interferon stimulates production of 1,25-dihydroxy vitamin D.i by normal human macrophages. Biochem Biophys Res Commun 1985 Mar; 127(2): 596-603
87. Fetchick DA, Bertolini DR, Sarin PS. el al. Production of 1,25dihydroxyvitamin D.i by human T cell lymphotropic virus-1transformed lymphocytes. J Clin Invest 1986 Aug; 78 (2): 592-6
88. Bar-ShavitZ,NoffD,EdelsleinS,etal. 1,25-Dihydroxyvitamin D.î and the regulation of the macrophage function. Calcif Tissue Int 1981; 33 (6): 673-6
89. Wientroub S, Winter CC, Wahl SM, et al, Effect of vitamin D deficiency on macrophage and lymphocyte function in the rat. Calcif Tissue Int 1989 Feb; 44 (2): 125-30
90. Thompson BY, Sivam G, Britigan BE, et al, Oxygen metabolism of the HL-60 cell line: comparison of the effects of monocytoid and neutrophilic differentiation. J Leukoc Biol 1988 Feb; 43 (2): 140-7
91. Tsoukas CD, Watry D, Escobar SS, et al, Inhibition of interleukin-l production by 1,25-dihydroxy vitamin D}. J Clin Endocrinol Metabol 1989 Jul; 69 (1): 127-33
92. Müller K, Svenson M, Bendtzen K, l ct,25-Dihydroxyvitamin D.i and a novel vitamin D analogue MC 903 are potent inhib-itors of human interleukin 1 in vitro. Immunol Lett 1988 Apr; 17(4):361-6
93. BlifeldC, Prehn JL, Jordan SC, Stimulus-specific l,25(OHhD, modulation of TNF and IL-1-beta gene expression in human peripheral blood mononuclear cells and monocytoid cell lines. Transplantation 1991 Feb; 51 (2): 498-503
94. Zarrabeitia MT, Riancho JA, Olmos JM, et al, Effect of calcitriol on the secretion of prostaglandin Ei, interleukin 1, and tumor necrosis factor a by human monocytes. Bone 1992; 13 (2): 185-9
95. Müller K, HaahrPM, Diamant M, et al, 1,25-Dihydroxyvitamin D.i inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992 Nov; 4 (6); 506-12
96. Müller K, Diamant M, Bendtzen K, Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D.i. Immunol Lett 1991 May; 28 (2): 115-20
97. Lemire JM, Beck L, Faherty D, et al, 1,25-Dihydroxy vitamin D.i inhibits the production of IL-12 by human monocytes and B cells. In; Norman AW, Bouillon R, Thomasset M, editors. Vitamin D, a pluripotent steroid hormone; structural studies, molecular endocrinology and clinical applications. Berlin: Walter de Gruyter, 1994: 534-5
98. Koren R, Ravid A, Rotem C, et al, 1,25-Dihydroxy vitamin Di enhances prostaglandin Ei production by monocytes, a mechanism which partially accounts for the antiproliferative effect of l,25(OH):Di on lymphocytes. FEBS Lett 1986 Sep; 205 (1): 113-6
99. Tsoukas CD, 1,25-Dihydroxy vitamin Di: a novel immunoregulatory hormone. Science 1984 Jun; 224 (4656): 1438-40
100. Jordan SC, Toyoda M, Prehn J, et al, 1,25-Dihydroxy vitamin D) regulation of interleukin-2 and interleukin-2 receptor levels and gene expression in human T cells. Mol Immunol 1989 Oct; 26 (10): 979-84
101. Smith J, Jenkins AS, Caine S, et al, The influence of calciotrophic hormones on lymphocyte transformation and interleukin-2 production in human mononuclear cells. J Clin Lab Immunol 1990 Oct; 33 (2): 49-54
102. Müller K, 0dum N, Bendtzen K, 1,25-Dihydroxy vitamin D.i selectively reduces interleukin-2 levels and proliferation of human T cell lines in vitro. Immunol Lett 1993 Feb; 35 (2): 177-82
103. Rigby WFC, Denome S, Fanger MW, Regulation of lymphokine production and human T lymphocyte activation by 1,25dihydroxyvitamin D.i. J Clin Invest 1987 Jun; 79(6): 1659-64
104. ReichelH,KoefflerHP.ToblerA.etal. la,25-Dihydroxyvitamin D.i inhibits y-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sei USA 1987 May; 84 (10): 3385-9
105. Tobler A, Gasson J, Reichel H, et al, Granulocyte-macrophage colony-stimulating factor: sensitive and receptor-mediated regulation by 1,25-dihydroxy vitamin D.i in normal human peripheral blood lymphocytes. J Clin Invest 1987 May; 79 (5): 1700-5
106. Tobler A, Miller CW, Norman AW, et al, 1,25-Dihydroxy vitamin Dj modulates the expression of a lymphokine (granulocytemacrophage colony-stimulating factor) post-transcriptionally. J Clin Invest 1988 Jun; 81 (6): 1819-23
107. Iho S, Takahashi T, Kura F, et al, The effect of 1,25-dihydroxyvitamin D.i on in vitro immunoglobulin production in human B cells. J Immunol 1986 Jun; 136 (12): 4427-31
108. Müller K, Heilmann C, Poulsen LK, et al, The role of monocytes and T cells in 1,25-dihydroxyvitamin D.i mediated inhibition of B cell function in vitro. Immunopharmacology 1991 MarApr; 21 (2): 121-8
109. Righy WFC, The immunohiology of vitamin D. Immunol Today 1988 Feb; 9 (2): 54-8
110. Adams JS, Vitamin D metabolite-mediated hypercalcemia. Hypercalcemia 1989 Sep; 18 (3): 765-78
111. Lemire JM, Clay Archer D, Beck L, et al, Immunosuppressive actions of 1,25-iIihydroxyvitamin Dî: preferential inhibition of Thl functions. J Nutr 1995 Jun; 125 (6S): 1704S-8S
112. Muller K, Bendtzen K, Inhibition of human T lymphocyte proliferation and cytokine production by 1,25-dihydroxyvitamin D,: differential effects on CD45RA+ and CD45RO+ cells. Autoimmunity 1992; 14(1): 37-43
113. Scott P, IFN-y modulates the early development ofThl andfh2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991 Nov; 147(9): 3149-55
114. Manetti R, Parronchi P, Giudizi MG, et al. Natural killer cell stimulatory factor (interleukin 12) induces T helper type 1 (Thl(-specific immune responses and inhibits the development of lL-4-producing Th cells. J Exp Med 1993 Apr: 177 (4): 1199-204
115. Leung KH, Inhibition of human natural killer cell and lymphokine-activated killer cell cytotoxicity and differentiation by vitamin D;. Scand J Immunol 1989 Aug: 30 (2): 199-208
116. Merino F, Alvarez-Mon M, De la Hera A, et al, Regulation of natural killer cytotoxicity by 1,25-dihydroxy vitamin D(. Cell Immunol 1989 Feb; 118(2): 328-36
117. Lillevang ST, Rosenkvist J, Andersen CB. et al. Single and combined effects of the vitamin D analogue KHI060 and cyclosporin A on mercuric-chloride-induced autoimmune disease in the BN rat. Clin Exp Immunol 1992 May: 88 (2l: 301-6
118. Koizumi T, Nakao Y. Matsui T, et al. Effects of corticosteroid and l,24R-dihydroxy-vitamin D.i administration on lymphoproliferative and autoimmune disorders in MRL/MP-Lpr/lpr mice. Int Arch Allergy Appl Immunol 1985; 77 (4): 396-404
119. Abe J, Takita Y, Nakano T, et al, 22-Oxa-1 a-25-dihydroxy vitamin Di: a new synthetic analogue of vitamin D having a potent immunoregulating activity without inducing hypercalcaemia in mice. In: Cohn DV, Glorieux FH, Martin TJ, editors. Calcium regulation and bone metabolism. Amsterdam: Elsevier. 1990: 146-51
120. Branisteanu DD, Leenaerts P, Bouillon R. et al. Partial prevention of active Heymann nephritis by I a.25-dihydroxy vitamin D.i. Clin Exp Immunol 1993 Dec: 94 |3): 412-7
121. Hattori M, Effect of loc.25(OH):D.i on experimental rat nephrotoxic serum nephritis. Nippon Jinzo Gakkai Shi 1990 Feh; 32(2): 147-59
122. Fournier C, Gepner P, Sadouk M, et al. In vim beneficial effects of cyclosporin A and 1,25-dihydroxy vitamin Dion the induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990 Jan: 54 ( 1 ): 53-63
123. Boissier MC, Chiocchia G, Fournier C. Combination ofcyclosporine A and calcitriol in the treatment of adjuvant arthritis. J Rheumatol 1992 May; 19 (5): 754-7
124. Lemire JM, Clay Archer D. 1.25-Dihydroxyvitamin D.i prevents the in wru induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991 Mar: 87(3): 1103-7
125. Branisteanu DD, Waer M. Bouillon R. et al. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and la.25-(OH):Di. J Neuroimmunol. In press
126. Lemire JM, 1.25-Dihydroxy-24-oxo-l6ene-vitamin D;, a renal metabolite of the vitamin D analog 1.25-dihydroxy-l6ene-vitamin Di. exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. Endocrinology 1994 Dec; 135(6): 2818-21
127. Mathieu C, Laureys J, Bouillon R, et al. 1,25-Dihydroxyvitamin Dî prevents insulitis in NOD mice. Diabetes 1992 Nov: 41 (II): 1491-5
128. Mathieu C, Waer M. Bouillon R, et al. Prevention of autoimmune diabetes in Nod mice by 1.25-dihydroxyvitainin Di. Diabetologia 1994 Jun: 37 (6): 552-8
129. Mathieu C, Casteels K, Bouillon R, et al. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin Di. KHI060. Endocrinology 1995 Mar; 136 (3): 866-72
130. Inaha M, Nishizawa Y, Song K. et al. Partial protection of Icthydroxyvitamin Di against the development of diabetes induced by multiple low-dose streptozotocin injection in CD-I mice. Metabolism 1992 Jun; 41 (6): 631-5
131. Chandler C, Passaro Jr E. Transplant rejection: mechanisms and treatment. Arch Surg 1993 Mar; 128 (3): 279-83
132. Mathieu C, Bouillon R, Waer M. et al. Prevention of autoimmune destruction of transplanted islets in spontaneously diabetic NOD mice by KH 1060. a 20-epi analogue of vitamin D: synergy with cyclosporin A. Transplant Proc 1994 Dec: 26 (6): 3128-9
133. Mathieu C, Waer M, Bouillon R. et al. Activated form of vitamin D [ l,25(OH)iDi| and its analogs are dose-reducing agents for cyclosporine in vitro and in vivo. Transplant Proc l994Oct:26(5): 3048-9
134. Lemire JM, Clay Archer D. Khulkarni A. et al. Prolongation of the survival of murine cardiac allografts by the vitamin D; analogue l.25-dihydroxy-A'-cholecalciferol. Transplantation 1992Oct:54(4): 762-3
135. Jordan SC, Nigata M. Müllen Y. 1.25-Dihydroxy vitamin D; prolongs rat cardiac allograft survival. In: Norman AW. Schaefer K, Grigoleit H-G. et al., editors. Vitamin D: molecular, cellular and clinical endocrinology. Berlin: Walter de Gruyter, 1988: 334 5
136. Jordan SC, Shibuka R. Müllen Y. 1.25-Dihydroxy vitamin D; prolongs skin graft survival in mice. In: Norman AW, Schaefer K, Grigoleit H-G. et al., editors. Vitamin D: molecular, cellular andclinical endocrinology. Berlin: Walter de Gruyter. 1988: 346-7
137. Veyron P, Pamphile R. Binderup L. et al. Two novel vitamin D analogues, KH 1060 and CB 966, prolong skin allograft survival in mice. Transplant Immunol 1993; 1(1): 72-6
138. Lewin E, Olgaard K. The in vivo effect of a new in vitro, extremely potent vitamin Di analog KH 1060 on the suppression of renal allograft rejection in the rat. Calcif Tissue hit 1994 Feb:54(2):I50-4
139. Bouillon R, Okamura WH. Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995 May; 16(2): 200-57
140. Bouillon R, Allewaert K, Branisteanu D. et al. Non-hypercalcémie pharmacological aspects of vitamin D analogs. Biochem Pharmacol 1995; 50 15): 577-83
141. Bouillon R, Allewaert K,Tan BK.etal. Vitamin-D analogs with low affinity for the vitamin-D binding protein: enhanced in vilro and decreased in vivo activity. J Bone Miner Res 1991 Oct; 6(10): 1051-7
142. Imai Y, Pike JW, Koeffler HP. Potent vitamin Di analogs: their abilities to enhance transactivation and to bind to the vitamin D, response element. Leuk Res 1995 Mar; 19 (3): 147 58
143. Zhao J, Marcelis S, Verstuyf A. étal. Potentialisation of vitamin D (analogs) by cytochrome P-450 en/yme inhibitors is ana-
144. log- and cell-type specific, In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D, a pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Berlin: Walter de Gruyter, 1994: 186-7
145. Van Baelen H, Convents R, Bouillon R, Activity of vitamin D analogs in co-transfected cos-7 cells. In: Norman AW, Bouillon R, Thomasset M, editors. Vitamin D, a pluripotent steroid hormone: structural studies, molecular endocrinology and clinical applications. Berlin: Walterde Gruyter, 1994: 77-8
146. Carlberg C, Mathiasen IS, Saurai J-H, et al, The 1,25-dihydroxyvitamin D, (VD) analogues MC903, EB1089 and KH1060 activate the VD receptor: homodimers show higher ligand sensitivity than heterodimers with retinoid X receptors. J Steroid Biochem Mol Biol 1994 Nov; 51 (3-4): 137-42
147. Binderup L, Immunological properties of vitamin D analogues and metabolites. Biochem Pharmacol 1992 May; 43 (9): 1885-92
148. Rigby WFC, Yirinec B, Oldershaw RL, et al, Comparison of the effecls of 1,25-dihydroxyvitamin Dj on T lymphocyte subpopulations. Eur J Immunol 1987 Apr; 17 (4): 563-6
149. Di Padova F, Pharmacology of cyclosporine (Sandimmune). V. Pharmacological effects on immune function: in vitro studies. Pharmacol Rev 1989 Sep; 41 (3): 373-405
150. Calder VL, Bellamy AS, Owen S, et al, Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis. Clin Exp Immunol 1987 Dec; 70 (3): 570-7
151. Reed JC, Abidi AH, Alpers JD, et al, Effect of cyclosporin A and dexamethasone on interleukin 2 receptor gene expression. J Immunol 1986 Jul; 137 (1): 150-4
152. Gupta S, Pass D, Shimizu M, et al, Potentiation of immunosuppressive effects of cyclosporin A by la,25-dihydroxy vitamin D3. Cell Immunol 1989 Jul; 121 (2): 290-7
153. Mathieu C, Bouillon R, Rutgeerts O, et al, Potential role of 1,25(OH>2 vitamin Di as a dose-reducing agent for cyclosporine and FK506. Transplant Proc 1994 Dec; 26 (6): 3130
154. Gepner P, Amor B, FournierC, 1,25-Dihydroxyvitamin D} potentiates the in vilro inhibitory effects of cyclosporin A on T cells from rheumatoid arthritis patients. Arthritis Rheum 1989 Jan; 32(1): 31-6
155. Burcelin RG, Eddouks M, Beylot M, et al. Hypersensitivity to insulin during remission in cyclosporin-treated IDDM patients. Diabetes Care 1993 Jun; 16 (6): 881-8
156. Scharp DW, Lacy PE, Santiago JV, et al, Results of our first nine intraportal islet allografts in type 1 insulin-dependent diabetic patients. Transplantation 1991 Jan; 51 (1): 76-85
157. Rudge P, Koetsier JC, Merlin J, et al, Randomised double blind controlled trial of cyclosporin in multiple sclerosis. J Neurol Neurosurg Psychiatry 1989 May; 52 (5); 559-65
158. Rudge P, Cyclosporine and multiple sclerosis: the cons. Neurology 1988 Jul; 38 (7 Suppl. 2): 29-30
159. Morris RE, Meiser BM, Wu J, et al, Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991 Feb; 23 (1 Pt 1): 521-4
160. Kahan BD, Gibbons S, Tejpal N, et al, Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3 and MLR proliferative and cytotoxicity assays. Transplant Proc 1991; 23 (I Pt 2): 1090-1
161. Kahan BD, Drug therapy: cyclosporine. N Engl J Med 1989 Dec; 321 (25): 1725-37
162. Schlosberg M, Movsowitz C, Epstein S, et al, The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology 1989 May; 124 (5): 2179-84
163. Katz IA, Jee WSS, Joffe II, et al, Prostaglandin £2 alleviates cyclosporin A-induced bone loss in the rat. J Bone Miner Res 19920ct;7(10): 1191-200
164. Cvetkovic M, Mann GN, Romero DF, et al, The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. Transplantation 1994 Apr; 57 (8): 1231-7
165. Julian BA, Laskow DA, Dubowsky J, et al, Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991 Aug; 325 (8): 544-50
166. Valantine HA, Long-term management and results in heart transplant recipients, Cardiol Clin 1990 Feb; 8(1): 141-8
167. Katz IA, Epstein S, Posttransplantation bone disease. J Bone Miner Res 1992 Feb; 7 (2): 123-6
168. Correspondence and reprints: Dr Roger Bouillon, Legendo, Onderwijs en Navorsing, Gasthuisberg, B-3000 Leuven, Belgium,